

EUROPEAN SYMPOSIUM

Optimal use of clotting factors and immunoglobulins

26-27 April 2013, Wildbad Kreuth, Germany

Duration: 2,5 days. Working language: English

PROGRAMME

THURSDAY 25 APRIL 2013

16:00-18:00

- Poster set-up for manufacturers
- Registration for participants
- Pre-meeting for speakers

19:00-21:30

- Buffet Dinner

FRIDAY 26 APRIL 2013

8:00 Welcome

Dr Karl-Heinz Buchheit, EDQM, Council of Europe

SESSION 1: General information on the clinical use of clotting factors and immunoglobulins

Moderator: *Karl-Heinz Buchheit*

Rapporteurs: *Rainer Seitz & Harvey Klein*

8:15-8:30

Key lecture

Optimal clinical use of blood and plasma derivatives
Background and perspectives

Harvey Klein, National Institute of Health, Bethesda, USA

8:30-9:15

Rationale for the meeting

Clinical use of immunoglobulins

Hans-Hartmut Peter, University of Freiburg, DE

Clinical use of clotting factors (plasma-derived and recombinant)

Wolfgang Schramm, University of Munich, DE

Regulations for plasma-derived and recombinant medicinal products

Rainer Seitz, Paul Ehrlich Institut, Langen, DE

9:15-9:30

Clinical challenges and access to clotting factor concentrates in haemophilia in Europe

Paul Giangrande, Churchill Hospital, Oxford, UK

9:30-9:45

Current data on the use of clotting factors and immunoglobulins in Europe

Patrick Robert, The Marketing Research Bureau, Inc, Orange, USA

9:45-10:00

Report on the outcome of the EDQM surveys

Karin Berger, University Hospital of Munich, DE

Jacqueline Kerr, Paul-Ehrlich-Institut, Langen, DE

10:00-10:30

Coffee break and poster viewing

SESSION 2: Clotting Factors

Moderators & Rapporteurs: *Wolfgang Schramm & Rainer Seitz*

- 10:30-10:45 Patients organisations' view - Access and unmet needs**
Brian O'Mahony, European Haemophilia Consortium (EHC), City, Country
- 10:45-11:05 New developments in clinical research and new treatment modalities – A clinician's perspective**
Pier Mannucci, IRCCS Ca' Granda Maggiore Policlinico Hospital Foundation, Milan, IT
- 11:05-11:25 Benefits and limitations with innovative clotting factor preparations**
Flora Peyvandi, University of Milan, IT
- 11:25-11:45 European clinical guidelines**
Cedric Hermans, Cliniques Universitaires Saint Luc, BE
- 11:45-12:00 European regulatory perspective**
Anneliese Hilger, Paul Ehrlich Institut, Langen, DE
- 12:00-12:15 Registries**
Mike Makris, Royal Hallamshire Hospital, Sheffield, UK
- 12:15-13:30 Lunch break and poster viewing**

SESSION 3: Immunoglobulins

Moderators & Rapporteurs: *Hans-Hartmut Peter, Isabella Quinti & Carrock Sewell*

- 13:30-13:45 Patients Organisations' view - Access and unmet needs**
Jose Drabwell, International Patient Organisation for Primary Immunodeficiencies
- 13:45-14:05 Clinically established indications in primary and secondary immunodeficiencies**
Helen Chapel, John Radcliffe Hospital, Oxford, UK
presented by Hans-Hartmut Peter
- 14:05-14:25 Immunomodulation: On-label and off-label Usage**
Ivo Van Schaik, University of Amsterdam, NL
- 14:25-14:40 European regulatory perspective**
Jacqueline Kerr, Paul Ehrlich Institut, Langen, DE
- 14:40-14:55 Demand Management Plan**
Carrock Sewell, Scunthorpe General Hospital, UK
- 14:55-15:10 Innovative products and new developments - cancelled**
Lennart Hammarström, Karolinska Institute, Stockholm, SE
- 15:10-15:25 Registries**
Bodo Grimbacher, University of Freiburg, DE
- 15:25-16:00 Coffee break and poster viewing**

SESSION 4: Working Groups Session

16:00-18:00 Working Group 1: Clotting factors

Moderators: *Pier Mannucci, Wolfgang Schramm*

Rapporteurs: *Pier Mannucci, Paul Giangrande, Wolfgang Schramm*

16:00-18:00 Working Group 2: Immunoglobulins

Moderators: *Hans-Hartmut Peter, Jacqueline Kerr*

Rapporteurs: *Hans-Hartmut Peter, Jacqueline Kerr, Isabella Quinti & Carrock Sewell*

18:00 Close of meeting

20:00 Evening Dinner

SATURDAY 27 APRIL 2013 – CLOSED MEETING

8:00-9:00 Interim reports from Working Groups

9:00-10:45 Discussion in the Working Groups

10:45-11:00 Coffee break

11:00-12:30 Final reports from the Working Groups

Moderators: *Rainer Seitz & Karl-Heinz Buchheit*

- Working Group 1: Clotting factor
- Working Group 2: Immunoglobulins

12:30-13:30 Lunch break

13:30-16:00 Conclusions and Recommendations

SCIENTIFIC PROGRAMME COMMITTEE

Prof Dr Rainer SEITZ

Ms Karin BERGER

Dr Marie-Emmanuelle BEHR-GROSS

Dr Anneliese HILGER

Dr Karl-Heinz BUCHHEIT

Dr Jacqueline KERR

Prof Dr Wolfgang SCHRAMM

Prof Dr Hans-Hartmut PETER

Meeting Venue: see http://www.hss.de/fileadmin/media/downloads/Anfahrtsskizze_Wildbad-Kreuth.pdf <http://www.hss.de/bildungszentren/wildbad-kreuth.html>